

Aberystwyth University

Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products

Baptista, Rafael; Bhowmick, Sumana; Shen, Jianying; Mur, Luis A. J.

Published in:
Molecules

DOI:
[10.3390/molecules26020475](https://doi.org/10.3390/molecules26020475)

Publication date:
2021

Citation for published version (APA):

Baptista, R., Bhowmick, S., Shen, J., & Mur, L. A. J. (2021). Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products. *Molecules*, 26(2), [475]. <https://doi.org/10.3390/molecules26020475>

Document License CC BY

General rights

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400
email: is@aber.ac.uk

Article

Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products

Rafael Baptista ¹, Sumana Bhowmick ¹, Jianying Shen ^{2,*} and Luis A. J. Mur ^{1,2,*}

¹ Institute of Biological, Environmental and Rural Sciences, Penglais Campus, Aberystwyth University, Aberystwyth, Wales SY23 2DA, UK; rafaelb4@gmail.com (R.B.); sub23@aber.ac.uk (S.B.)

² Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

* Correspondence: jyshen@icmm.ac.cn (S.J.); lum@aber.ac.uk (L.A.J.M.)

Abstract: Tuberculosis (TB) is a major global threat, mostly due to the development of antibiotic-resistant forms of *Mycobacterium tuberculosis*, the causal agent of the disease. Driven by the pressing need for new anti-mycobacterial agents several natural products (NPs) have been shown to have in vitro activities against *M. tuberculosis*. The utility of any NP as a drug lead is augmented when the anti-mycobacterial target(s) is unknown. To suggest these, we used a molecular reverse docking approach to predict the interactions of 53 selected anti-mycobacterial NPs against known “drug-gable” mycobacterial targets ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13. The docking scores/binding free energies were predicted and calculated using AutoDock Vina along with physicochemical and structural properties of the NPs, using PaDEL descriptors. These were compared to the established inhibitor (control) drugs for each mycobacterial target. The specific interactions of the bisbenzylisoquinoline alkaloids 2-nortiliacorinine, tiliacorine and 13'-bromotiliacorinine against the targets PknB and DprE1 (−11.4, −10.9 and −9.8 kcal·mol^{−1}; −12.7, −10.9 and −10.3 kcal·mol^{−1}, respectively) and the lignan α-cubebin and Pks13 (−11.0 kcal·mol^{−1}) had significantly superior docking scores compared to controls. Our approach can be used to suggest predicted targets for the NP to be validated experimentally, but these in silico steps are likely to facilitate drug optimization.

Keywords: tuberculosis; reverse docking; natural products; anti-mycobacterial agents



Citation: Baptista, R.; Bhowmick, S.; Shen, J.; Mur, L.A.J. Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products. *Molecules* **2021**, *26*, 475. <https://doi.org/10.3390/molecules26020475>

Academic Editor: Giosuè Costa
Received: 16 December 2020
Accepted: 11 January 2021
Published: 18 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Tuberculosis (TB) is the leading cause of death from infectious diseases, with 10 million new cases in 2017. About 1.7 billion people are estimated to have latent TB infection, and are at risk of developing active TB disease during their lifetime [1]. The emergence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) TB is primarily due to the improper use of the first-line anti-tubercular drug. The increased prevalence of such strains has become a major obstacle in the treatment of TB and also a serious financial burden on the health care sector. As a result, there is an urgent need for new cost-effective anti-TB drugs with new mechanisms of action and less chance of developing resistance [2].

TB drug discovery has been based on the use of combinatorial chemistry and high-throughput screening strategies in drug discovery, but recently, there has been an increased interest in plant-based natural products (NP) as drugs [2]. Plants are an important source of secondary metabolites that can have enormous therapeutic potential. They are still used in traditional medicine in such nations as China and in economically developing countries. Often knowledge of medicinal plants is passed verbally from generation-to-generation without any proper documentation or scientific validation. However, medicinal plants still represent a resource that can be further explored for potential “hit” compounds with significant biological activity, i.e., drug leads [3]. These hit compounds are typically found in biochemically complex extracts, and their identification can be considered to be equivalent to searching for a “needle in a haystack”. This is usually approached through

sequential rounds of bioassay informed purification but could be considerably accelerated if candidate chemicals could be screened against known and “druggable” drug targets. Crucially, the identification of these targets facilitates drug optimization for improved efficacy and such reduced cytotoxicity [2].

Reverse docking is widely used to model interactions at the atomic level between a small molecule (ligand) and a known macromolecule [4]. Molecular docking and other bioinformatic tools represent cost-effective approaches to screen potential compounds prior to in vitro cell culture-based assays or chemical modifications to accelerate the overall drug discovery process. The importance of the reverse docking technique was evident in its recent application in the identification of p38-alpha kinase as the molecular target of anti-inflammatory natural products hybrids. This approach was directly linked to the identification of esculentoside A's target and mode of action [5,6]. In this present study, we exploited the existing knowledge of anti-tubercular drug targets to predict the potential modes of action of NPs known to have activity against TB. Seven molecular targets of *M. tuberculosis*—ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13—were selected as these are essential for bacterial survival, and their inhibition will affect mycobacterial metabolism [7–18]. We herein predict the binding of the NPs in comparison with the established inhibitor of the molecular target, which was referred to as the control. We show that the specific interactions of the bisbenzylisoquinoline alkaloids 2-nortiliacorinine, tiliacorine and 13'-bromotiliacorinine against PknB and DprE1 and the lignan α -cubebin with Pks13 had significantly superior docking scores. The predicted interactions here reported should facilitate in vitro validation studies.

2. Results

A total of 53 NPs with reported anti-mycobacterial activity ($\leq 100 \text{ mg} \cdot \text{mL}^{-1}$) were selected [3] (Table 1). These were subjected to a series of in silico predictions to assess their “druggability” and suggest their targets. The 53 NPs were organized into chemical classes and then assessed for their individual binding energy against established antimicrobial target proteins, ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, which were retrieved from Protein Data Bank (PDB). For ease of comparison, the binding energies associated with all groups of studied NPs against each mycobacterial target are given as box-plots and compared to the binding of the known anti-TB drug hit for each protein (Figure 1, control bindings are shown with a dashed line).

Table 1. Plants and their molecules active against different *Mycobacterium* strains. ^a mono-resistant clinical and non-clinical isolates, ^b multidrug-resistant (MDR) clinical and non-clinical isolates, ^c mycobacteria other than *M. tuberculosis*, ^d *Mycobacterium tuberculosis*.

Plant Names	Active Phytomolecules	MIC ($\mu\text{g}/\text{mL}$)	References
<i>Andrographis paniculata</i>	Andrographolide	-	[19,20]
<i>Aristolochia brevipes</i> Benth.	6 α -7-Dehydro-N-formyl-nornantenine	>50 ^{a,b,d}	[21]
	N-Formylnornantenine	>50 ^{a,b,d}	
	Aristolactam I	12.5–25 ^{a,b,d}	
<i>Aristolochia taliscana</i> Hook and Arn.	Licarin A	3.12–25 ^{a,b,d}	[22]
	Licarin B	12.5–5 ^{a,b,d}	
	Eupomatenoid-7	6.25–50 ^{a,b,d}	
<i>Aristolochia elegans</i> Mast.	Fargesin	12–50 ^{a,b,d}	[23]
	(8R,8'R,9R)-Cubebin or α -Cubebin	50–100 ^{a,b,d}	
<i>Artemisia capillaris</i> Thunb.	Ursolic acid	12.5–50 ^{a,b,c,d}	[24,25]
	Hydroquinone	12.5–25 ^{a,b,c,d}	[25]

Table 1. Cont.

Plant Names	Active Phytomolecules	MIC ($\mu\text{g/mL}$)	References
<i>Azorella compacta</i> Phil., <i>A. madreporica</i> Clos.	Azorellanol	12.5 ^{b,d}	[26]
	Mulin-11,13-dien-20-oic acid	25–50 ^{b,d}	
	Mulinol	12.5–25 ^{b,d}	
<i>Beilschmiedia tsangii</i> Merr.	Beilschmin A	2.5 ^d	[27]
<i>Blepharodon nitidum</i> (Vell.) J.F. Macbr.	25-Hydroperoxycycloart-23-en-3 β -ol	25 ^b	[28]
<i>Citrullus colocynthis</i> (L.) Schrad.	Cucurbitacin-E-2- <i>o</i> - β - <i>d</i> -glucopyranoside	25–62.5 ^{a,b,c,d}	[29]
<i>Clavija procera</i> B. Stähl	Aegicerin	1.6–3.12 ^{a,b,d}	[30]
<i>Curcuma longa</i> L.	Curcumin	100 ^d	[31]
	Demethoxycurcumin	50 ^d	
	Bisdemethoxycurcumin	25 ^d	
<i>Diospyros anisandra</i> S.F. Blake	Plumbagin	1.5–62.5 ^{b,c,d}	[32,33]
	Maritinone or 8,8'-Biplumbagin	3.12 ^{b,d}	[32]
	3,3'-Biplumbagin	3.12 ^{b,d}	
<i>Diospyros montana</i>	Diospyrin	8–250 ^{b,c,d}	[33,34]
<i>Euclea natalensis</i> A. DC.	7-Methyljuglone	0.5–1.25 ^{a,b,d}	[34]
	Mamegakinone	100 ^d	[35]
	Isodiospyrin	10 ^d	
	Neodiospyrin	10 ^d	
	Shinanolone	100 ^d	
<i>Ferula communis</i> Linn.	Ferulenol	1.25 ^c	[36]
<i>Feniculum vulgare</i> Mill.	5-Hydroxy-furanocoumarin or bergaptol	100–200 ^b	[37]
<i>Juniperus communis</i> subsp. <i>communis</i> var. <i>communis</i> L.	Totarol	2–25 ^{a,c,d}	[38]
	Ferruginol	5 ^c	[39]
	Sandaracopimeric acid	30 ^c	
	4-Epiabietol	60 ^c	
<i>Justicia adhatoda</i> L. or <i>Adhatoda vesica</i>	Vasicine	200 ^d	
<i>Kaempferia galangal</i> L.	Ethyl- <i>p</i> -methoxycinnamate	50–100 ^{b,d}	[40]
<i>Lantana hispida</i> Kunth	Oleanolic acid	25–100 ^{a,b,c,d}	[24,41]
<i>Larrea tridentata</i> Coville	Dihydroguaiaietic acid	12–50 ^{b,d}	[42]
	4-Epi-larreatricin	25–50 ^{b,d}	
<i>Plectranthus grandidentatus</i> Gurke	Abietane	3.12–25 ^{b,d}	[43]
<i>Plumeria bicolor</i> Ruiz and Pav.	Plumericin	1.5–2 ^{b,d}	[44]
	Isoplumericin	2–2.5 ^{b,d}	
<i>Struthanthus concinnus</i>	Obtusifoliol	50 ^d	[45]
<i>Tabernemontana elegans</i> Stapf. or <i>Tiliacora triandra</i>	Tiliacorinine	3.12–6.25 ^{b,d}	[46]
	2'-Nortiliacorinine	1.5–6.25 ^{b,d}	
	13'-Bromotiliacorinine	1.5–6.25 ^{b,d}	

Table 1. Cont.

Plant Names	Active Phytomolecules	MIC (μg/mL)	References
<i>Ventilago madraspatana</i>	Emodin	4–128 ^{b,c}	[33]
<i>Vetiveria zizanioides</i>	α-Curcumene	31.25–125 ^{a,b,c}	[47]
	Valencene	62.5–250 ^{a,b,c}	
	Selina-3,7(11)-diene		




Figure 1. Binding energies ($\text{kcal}\cdot\text{mol}^{-1}$) of groups of selected natural products (alkaloids, coumarins, diterpenoids, lignans/neolignans, polyphenols, quinones, sesquiterpenoids, triterpenoids and others) and controls (represented with dashed lines) against mycobacterial targets ClpP1P2, InhA, DprE1, KasA, PanK, PknB and Pks13. Control inhibitors of each protein are, respectively, ZIL (N-[(benzyloxy)carbonyl]-l-isoleucyl-l-leucine), BTZ043 (bedaquiline), isoniazid, TLM (thiolactomycin), ZVT(2-chloro-N-[1-(5-[[2-(4-fluorophenoxy)ethyl]sulfanyl]-4-methyl-4H-1,2,4-triazol-3-yl)ethyl]benzamide), MIX(1,4-dihydroxy-5,8-bis([2-[(2-hydroxyethyl)amino]ethyl]amino)-9,10-antracenedione) and I28(ethyl-5-hydroxy-4-[(4-methylpiperidin-1-yl)methyl]-2-phenyl-1-benzofuran-3-carboxylate).

Three targets, InhA, Pks13 and DprE1, exhibited poor binding to all of the studied NPs. Only a few alkaloids and quinones exhibited lower energies (-11.4 to -10.5 $\text{kcal}\cdot\text{mol}^{-1}$) than the control drug isoniazid (-10.4 $\text{kcal}\cdot\text{mol}^{-1}$) against InhA. Considering Pks13, only one neolignan displayed lower energy (-11.0 $\text{kcal}\cdot\text{mol}^{-1}$) than the control drug I28 (ethyl 5-hydroxy-4-[(4-methylpiperidin-1-yl)methyl]-2-phenyl-1-benzofuran-3-carboxylate) (-10.5 $\text{kcal}\cdot\text{mol}^{-1}$). Similarly, only alkaloids displayed favorable binding energies (-12.7 to -10.2 $\text{kcal}\cdot\text{mol}^{-1}$), compared to the control, BTZ043 (bedaquiline) (-10.1 $\text{kcal}\cdot\text{mol}^{-1}$) against DprE1. Indeed, alkaloids exhibited very low binding energies (-11.4 to -8.7 $\text{kcal}\cdot\text{mol}^{-1}$) against PknB, when compared with the control inhibitor MIX (1, 4-dihydroxy-5,8-bis([2-[(2-hydroxyethyl)amino]ethyl]amino)-9,10-antracenedione) (-7.7 $\text{kcal}\cdot\text{mol}^{-1}$). In contrast, KasA and ClpP1P2 were shown to have some binding energy to a wide range of natural product classes. For KasA and ClpP1P2, binding was seen with coumarins, lignans/neolignans, polyphenols and quinones. KasA is also bound by sesquiterpenoids and ClpP1P2, by triterpenoids. Although the PanK is predicted to bind to different classes of NPs, the alkaloids and quinones had lower binding energies (-10.5 to

$-8.5 \text{ kcal}\cdot\text{mol}^{-1}$) compared with the control ZVT (2-chloro-*N*-[1-(5-([2-(4-fluorophenoxy)ethyl]sulfanyl)-4-methyl-4*H*-1,2,4-triazol-3-yl)ethyl]benzamide) ($-8.3 \text{ kcal}\cdot\text{mol}^{-1}$).

The average of MW presented by conventional anti-TB drugs [48] ($358.5 \text{ g}\cdot\text{mol}^{-1}$) contrasted with our NPs that typically had lower binding energies ($\text{MW} > 500 \text{ g}\cdot\text{mol}^{-1}$). However, the number of H-bonds acceptors of the NPs matched those of H-bonds acceptors of conventional anti-TB drugs [48], the majority of which were below 10 H-bonds acceptors. The same is observed with the number of rotational bonds, since 88% of conventional anti-TB drugs have less than 10 rotational bonds [48].

PaDEL-Descriptor was used to assess the key physicochemical properties necessary for an optimal binding between the NP with ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, compared to each respective control drug. PaDEL-Descriptor provided molecular weight (MW), partition coefficient (xLogP), rotatable bonds (nRotB), H-bond donors (nHBDon_Lipinski), H-bond acceptors (nHBAcc_Lipinski) and topological polar surface area (TopoPSA) (Supplementary Table S3). All components were assessed and checked for toxicity and drug-likeness employing SWISS-ADME [49] including Lipinsky, Ghose, Veber, Egan, Muegge, PAINS [50], and Brenk filters [51]. SwissADME evaluation did not post PAINS alert for the molecules with higher binding energy (Supplementary Table S4).

For ClpP1P2, InhA and PanK, there was a clear tendency for molecules with a higher topological polar surface area to have more favorable binding energies. This is due, in part, to the low binding energies of quinones against these three protein targets (Supplementary Figure S1). Higher MW appeared to have lower binding energies against ClpP1P2, InhA, DprE1, PanK and PknB. In this higher MW category of natural product, lower binding energies, usually lower than the control inhibitor, were mostly seen with triterpenoids and sesquiterpenoids (Supplementary Figure S2). When the lipophilicities of the NPs were analyzed compared to binding energies, no particular tendency was observed (Supplementary Figure S3). The NP with more favorable binding energies did not exhibit distinctive partition coefficients as indicated by xLogP values. For PanK, DprE1 and PknB, a higher number of H-bond acceptors (maximum of 8) was associated with lower binding energies. No similar trend was seen for the number of H-bond donors (Supplementary Figures S4 and S5). NPs with smaller rotation bonds were often linked to lower binding energies (Supplementary Figure S6).

Unsupervised principal component analysis (PCA) was used to provide a multivariate comparison of the physicochemical parameters of the selected NPs and 14 licensed anti-TB drugs (Figure 2). There was a large clustering of most NPs and anti-TB drugs, suggesting a significant commonality of properties. However, six anti-TB drugs (isoniazid, ethambutol, streptomycin, kanamycin, amikacin and levofloxacin, large red circle in Figure 3) do not cluster with the NPs mainly due to their high hydrophilicity. The three aminoglycosides—streptomycin, kanamycin and amikacin—also exhibit a high number of H-bonds donors ($n > 10$), which does not conform to one of “Lipinski’s rule of five”. Some NPs (selina-3,7(11)-diene, abietane and α -curcumene), represented in a large green circle in Figure 3, possessed distinctive chemical properties due to lack of any H-bond acceptors or donors. This would exclude them from being possible drug candidates without further derivatization.

Subsequently, a structural study was undertaken with the NPs that exhibited the most favorable anti-mycobacterial profiles, i.e., show lower energies than the control inhibitor (Figure 1). Thus, the interaction between the bisbenzylisoquinoline alkaloids 2-nortiliacorinine, tiliacorine and 13'-bromotiliacorinine against the targets PknB and DprE1 were modeled.

The interaction of tiliacorine, nortiliacorinine and 13'-bromotiliacorine with PknB is shown in Figure 3 and exhibited binding energies of -11.4 , -10.9 , and $-9.8 \text{ kcal}\cdot\text{mol}^{-1}$, respectively. These values are significantly lower than the binding energy found for the control drug, MIX ($-7.7 \text{ kcal}\cdot\text{mol}^{-1}$). The best docking positions of each of the three NPs were compared, and these showed considerable overlap (Figure 4). Such commonality of interaction could be related to inhibitory function and could guide drug optimization.

In particular, a key feature here revealed is the interactions of the hydrophobic core of these NPs with PnkB [49] a feature also seen with the planar dihydroxyanthraquinone moiety of the control drug.




Figure 2. 2D-PCA (A) and 3D-PCA (B) of the physicochemical parameters of 53 analyzed natural products (NP) and 14 anti-TB drugs (D). In one cluster, NP and D share similar physical and chemical properties, but two other clusters are unique of D (larger red circle) and another for NPs (larger green circle).




Figure 3. Molecular interactions of the best docking positions of tiliacrine (A), nortiliacrinine (B) and 13'-bromotiliacrine (C) against PknB. Hydrogen bonds are shown as yellow dashed lines.

The predicted interactions of tiliacrine, nortiliacrinine and 13'-bromotiliacrine with DprE1 were also visualized (Figure 5). Again, the interactions for all these NPs appeared to nearly superimpose. These showed better binding energies against DprE1, -12.7 , -10.9 , and -10.3 kcal·mol $^{-1}$, respectively, than the benzothiazinethione drug control BTZ043 (-10.1 kcal·mol $^{-1}$). The binding of DprE1 to tiliacrine, nortiliacrinine and 13'-bromotiliacrine, is stabilized by several non-covalent interactions. The LigPlot+ analysis shows that key van der Waals interactions with the residues Trp230, Val365, Lys367, Lys134, Tyr415, His132, Pro116, Ile131, Ala417, Lys418, Arg58, Thr118, Trp16, Tyr60, Gly117 and Tyr314 are responsible for the low binding energies of these structures with DprE1.




Figure 4. Superposition of the best docking positions of tiliacorine (pink), nortiliacorinine (orange) and 13'-bromotiliacorine (green) against PknB.




Figure 5. Superposition of best docking position of tiliacorine (pink), nortiliacorinine (orange) and 13'-bromotiliacorine (green) against DprE1.

The interaction between the lignan α -cubebin and Pks13 was examined (Figure 6) as it had a lower docking scoring ($-11.0 \text{ kcal}\cdot\text{mol}^{-1}$) compared to the control I28 ($-10.5 \text{ kcal}\cdot\text{mol}^{-1}$). α -cubebin interacts with Pks13 via two H-bonds with the residues Asp1644 and Gln1633 and several hydrophobic interactions with the residues Tyr1637, Ser1636, Phe1670, Ile1643, Tyr1663, Tyr1674, Ala1667, Asn1640 and Arg1641. The interaction with the residues Tyr1663, Tyr1674, Asn1640, Asp1644 and Gln1633 are also key features in the binding of the control drug I28 against Pks13 [10].




Figure 6. Molecular interactions of the best docking position of α -cubebin against Pks13. Hydrogen bonds are evidenced with yellow dashed lines.

3. Discussion

Predictions of molecular docking are now well-established when assessing the interactions between ligands and targets. The use of docking approaches has been facilitated by the development of suitable software such as GOLD, FlexX, FRED, DOCK and particularly, AutoDock Vina [52,53]. Such in silico reverse docking provides a numerical estimate of the likelihood of interaction of a compound to its target. This approach can be extended to identify the proteins which are likely in vivo binding sites, and therefore possible modes of action [54–56]. For example, the target of the antibacterial and anti-fungal natural product scytoscalarol was found to dock with EmbC, and this was linked with anti-mycobacterial activity. Other compounds such as the β -carboline alkaloids 8-hydroxymanzamine A and manzamine A were found to bind to the oxidoreductase InhA.

We here demonstrate how reverse docking can be used to assess large numbers of anti-mycobacterial NPs to suggest key interactions and imply a mode of action. Our approach was to examine the literature for NPs with anti-mycobacterial activities, but whose targets had not been previously characterized. Then, proteins known to be targeted by established anti-mycobacterial drug leads were screened using the NP chemical structures. The aim was to identify natural product interactions whose docking energies were as good as, or superior to, the established drug lead. The “druggable” mycobacterial targets ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, were all known to play important roles in maintaining mycobacterial viability. ClpP1P2 carries out the energy-dependent degradation of abnormal proteins within the cells during in vitro growth and infection [57]. DprE1 is a decaprenylphosphoryl-d-ribose oxidase involved in the biosynthesis of decaprenylphosphoryl-D-arabinose, an essential component of the mycobacterial cell wall and thus is essential for cell growth and survival [11,58]. InhA is a known target of isoniazid, a first-line anti-tuberculosis drug essential for the synthesis of mycolic acids. KasA is one of the enzymes responsible for the elongation of C16–26 fatty acyl primers in the FAS-II system for mycolic acid production of *M. tuberculosis* [59]. Pantothenate kinase (PanK) is a ubiquitous and essential enzyme that catalyzes the first step of the coenzyme A biosynthetic pathway [17]. PknB is a very well-characterized mycobacterial

serine/threonine-protein kinase that determines cell shape, morphology and possibly cell division [9]. Pks13 is a polyketide synthase that catalyzes the final condensation step in mycolic acid biosynthesis and is therefore essential for mycobacterial growth [60].

A key aspect of our approach was to identify several “drug-like” properties of the NPs and compare them with conventional anti-TB drugs [21]. Our analyses first assessed the chemical space occupied by the NPs against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, which were compared with the respective control inhibitor. This identified NPs which occupied the same “chemical space” as most of the anti-TB drugs. Only isoniazid, ethambutol, streptomycin, kanamycin, amikacin and levofloxacin, exhibited higher hydrophilicity compared to the NP. This could indicate that a few NPs have high cytotoxicity due to their higher relative lipophilicity. This will must be directly assessed through experimental testing.

Our structural study focused on bisbenzylisoquinoline alkaloids 2-nortiliacorinine, tiliacorinine and 13'-bromotiliacorinine against the targets PknB and DprE1. These bisbenzylisoquinoline alkaloids isolated from *Tiliacora triandra* roots, which are used in Thai cuisine, were very effective in suppressing 59 isolated MDR-TB strains with MICs in the range of 1.5–6.25 $\mu\text{g}\cdot\text{mL}^{-1}$ [46]. Structurally, these molecules are similar, but the minor differences resulted in different binding properties. Tiliacorinine, with the lowest binding energy, formed two hydrogen bonds with the residues Tyr94 and Phe19 of PknB. However, both nortiliacorinine and 13'-bromotiliacorinine only formed one stable hydrogen bond with Gly97 and Tyr94 (Figure 2). The bromide substitution at C-13 of 13'-bromotiliacorinine made the molecule less planar and thereby increased the binding energy through steric impedance as seen with the superimposed docked conformations of all three molecules (Figure 3). A key feature here revealed is the interactions of the hydrophobic core of these NPs and the planar dihydroxy anthraquinone moiety of the control in the hydrophobic “cage” of PknB [18].

The importance of our modeling approach for drug optimization was demonstrated by considering the binding of DprE1 to tiliacorinine, nortiliacorinine and 13'-bromotiliacorinine. The interaction with these NPs is stabilized by several non-covalent interactions, but crucially, these were distinctive from the binding simulations with BTZ043, where H-bonding, hydrophobic and ionic interactions are responsible for the stabilization of the complex [61]. Additionally, the residue Cys387, before identified as critical for covalently binding to Ct325 (3-(hydroxyamino)-*N*-[(1*R*)-1-phenylethyl]-5-(trifluoromethyl) benzamide) is not involved in the binding of any of the NPs. Overall, 13'-bromo-tiliacorinine has shown slightly better anti-mycobacterial activity (and lower cytotoxicity against MRC-5 cell lines) than tiliacorinine, nortiliacorinine, despite the higher binding energies here reported. Other biochemical assays are required to understand how the different chemical properties of these NPs influence bacterial uptake, metabolism and target binding. Nonetheless, the molecular interactions that we have defined can be used to inform chemical derivatization strategies aiming to increase specificity and decrease toxicity.

α -cubebin, a dibenzyl butyrolactone lignan, has been isolated from several species in various families, such as Aristolochiaceae, Myristicaceae, Rutaceae, and Piperaceae [62]. It is known to act as an insect antifeedant, as was noted with *Anticarsia gemmatilis* [63,64], as well as being anti-tubercular [24]. However, α -cubebin displays only moderate activity against several mono- and multi-drug-resistant isolates of *M. tuberculosis* (MICs ranging 50–100 $\mu\text{g}\cdot\text{mL}^{-1}$). Interestingly, it does not display cytotoxicity against LLCMK2 fibroblasts [65], suggesting that α -cubebin could merit derivatization to make it a better drug lead. α -cubebin exhibited a low binding energy value when docked to Pks13 and interacts with some of the key residues within Pks13 as the drug inhibitor I28. Additionally, unlike I28, α -cubebin has been predicted to bind to the protein tyrosine phosphatase B (PtpB) of *M. tuberculosis* [66]. This suggested that α -cubebin had some unique distinct binding characteristics with the *M. tuberculosis* proteome compared to I28. The information of α -cubebin's binding site will facilitate the optimization of this compound towards greater efficacy and selectivity.

In conclusion, we show how four promising NPs—tiliacorine, nortiliacorinine, 13'-bromotiliacorine and α -cubebin—have very lower binding energies than the respective controls against three “druggable” anti-mycobacterial targets PnKB, DprE1 and Pks13. Due to problems in obtaining the NPs from natural sources or complex total synthesis, the predicted *in silico* activity/binding will greatly facilitate drug optimization prior to further studies. Even though *in silico* and *in vitro* results are not always correlated, our approach based on reverse docking will generate hypotheses that should inform further *in vitro* validation studies and aid the optimization of new and promising anti-TB natural products.

4. Materials and Methods

4.1. Selected Anti-Tubercular Natural Products

Information about the selected anti-mycobacterial NPs and their activity against TB in minimum inhibitory concentration (MIC) is given in Table 1.

4.2. Ligand and Protein Selection

A total of 53 NPs with reported anti-mycobacterial activity ≤ 100 mg·mL^{−1} were selected. All chemical structures were retrieved from the PubChem compound database (NCBI) (<http://www.pubchem.ncbi.nlm.nih.gov>). The crystal structures and respective controls of ClpP1P2 (PDB ID: 4U0G) [8], DprE1 (PDB ID: 6HEZ) [67], InhA (PDB ID: 1ENY) [14], KasA (PDB ID: 2WGE) [16], PanK type 1 (PDB ID: 4BFT) [68], PknB (PDB ID: 2FUM) [18] and Pks13 (PDB ID: 5V3X) [10] were retrieved from the RCSB Protein Data Bank (PDB) database (<https://www.rcsb.org>).

4.3. Physicochemical and Structural Properties

In silico prediction of physicochemical and structural properties of the NPs was performed using PaDEL-descriptor [69] including the descriptors: nHBAcc_Lipinski (acceptor H-bonds), nHBDON_Lipinski (donor H-bonds), nRotB (number of rotation bonds), TopoPSA (topological polar surface area), MW (molecular weight) and XLogP (prediction of logP based on the atom-type method). Chemical space analyses were conducted with the NPs and 14 anti-TB drugs (ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, ciprofloxacin, levofloxacin, moxifloxacin, amikacin, kanamycin, linezolid, bedaquiline, clofazimine and delamanid), comparing the descriptors above. Unsupervised principal component analyses (PCA) were generated using the statistical analysis tool of Metaboanalyst 4.0 [70].

4.4. Docking

The extended PDB format, PDBQT, was used to coordinate files to include atomic partial charges [71]. All file conversions were performed using the open-source chemical toolbox Open Babel 2.3.2 [72]. The ligand and protein structures were optimized using AutoDock Tools software (AutoDock 1.5.6), which involved adding all hydrogen atoms to the macromolecule, which is a step necessary for correct calculation of partial atomic charges. Gasteiger charges are calculated for each atom of the macromolecule in AutoDock 1.5.6 [71].

NPs were docked against ClpP1P2, DprE1, InhA, KasA, PanK, PknB, and Pks13 along with each respective control inhibitors, ZIL (*N*-[(benzyloxy)carbonyl]-L-isoleucyl-L-leucine), BTZ043, isoniazid, TLM (thiolactomycin), ZVT, MIX, I28. Molecular docking calculations for all compounds with each of the proteins were performed using AutoDock Vina 1.1.2. Docking calculation was generated with the software free energy binding own scoring function. The binding affinity of the ligand was expressed in kcal·mol^{−1}. Nine different poses were calculated for each protein with the parameters num_modes = 9 and exhaustiveness = 16. The lowest energy conformation was chosen for binding model analysis. Molecular interactions between ligand and protein were generated and analyzed by LigPlot⁺ and depicted by PyMOL. PyMOL Molecular Graphics System, Version 2.0 Schrödinger (<http://www.pymol.org>) was used to prepare Figures.

To provide enough space for free movements of the ligands, the grid box was constructed to cover the active sites as defined using AutoDock 1.5.6. The grid points for ClpP1P2 were set to $18 \times 20 \times 12$, at a grid center of (x,y,z) $-84.697, -2.336, 38.022$ with a spacing of 1 Å. For DprE1, the grid points were set to $20 \times 20 \times 20$, at a grid center of (x,y,z) $14.99, -20.507, 37.226$ with a spacing of 1 Å. For InhA, the grid points were set to $26 \times 24 \times 22$, at a grid center of (x,y,z) $-5.111, 33.222, 13.410$ with a spacing of 1 Å. For KasA, the grid points were set to $20 \times 20 \times 20$, at a grid center of (x,y,z) $38.342, -7.033, 13.410$ with a spacing of 1 Å. For PanK, the grid points were set to $20 \times 20 \times 20$, at a grid center of (x,y,z) $-18.742, 13.919, 11.679$ with a spacing of 1 Å. For PknB, the grid points were set to $21 \times 20 \times 20$, at a grid center of (x,y,z) $61.518, 2.429, -25.588$ with a spacing of 1 Å. For Pks13, the grid points were set to $16 \times 18 \times 14$, at a grid center of (x,y,z) $3.954, 27.324, 8.499$ with a spacing of 1 Å.

Supplementary Materials: The following are available online, Figure S1: Topological polar surface (TopoPSA) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Figure S2: Molecular weight (MW) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Figure S3: Partition coefficient (XLogP) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Figure S4: Number of H-bonds acceptors (nHBAcc_Lipinski) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Figure S5: Number of H-bonds donors (nHBDDon_Lipinski) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Figure S6: Number of rotational bonds (nRotB) and binding energy of studied natural products against ClpP1P2, DprE1, InhA, KasA, PanK, PknB and Pks13, Table S1: Structures of the selected natural products, Table S2: Structures of inhibitor (control) drugs for each mycobacterial target, Table S3: The physiochemical properties using PaDel-descriptor: molecular weight (MW), partition coefficient (xLogP), rotatable bonds (nRotB), H-bond donors (nHBDDon_Lipinski), H-bond acceptors (nHBAcc_Lipinski) and topological polar surface area (TopoPSA), Table S4: List of ligand molecules chosen for testing with their corresponding drug likeness and medicinal chemistry filters using SWISS ADME.

Author Contributions: Conceptualization, R.B.; formal analysis, R.B. and S.B.; investigation, R.B. and S.B.; methodology, R.B.; project administration, L.A.J.M.; software, R.B. and S.B.; supervision, L.A.J.M. and S.J.; validation, L.A.J.M. and S.B.; writing—original draft, R.B. and S.B.; writing—review and editing, L.A.J.M., R.B., S.B. and S.J. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable. No new data were created or analyzed in this study.

Acknowledgments: R.B. was supported by a Natural Life Sciences Research Network PhD Scholarship. S.B. is thankful to Aberystwyth University for its AberDoc PhD Scholarship. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. WHO. *Global Tuberculosis Report 2018*; WHO Press: Geneva, Switzerland, 2018; ISBN 9789241565646.
2. Baptista, R.; Bhowmick, S.; Nash, R.J.; Baillie, L.; Mur, L.A. Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products. *Future Med. Chem.* **2018**, *10*, 811–822. [[CrossRef](#)] [[PubMed](#)]
3. Gupta, V.K.; Kumar, M.M.; Bisht, D.; Kaushik, A. Plants in our combating strategies against *Mycobacterium tuberculosis*: Progress made and obstacles met. *Pharm. Biol.* **2017**, *55*, 1536–1544. [[CrossRef](#)] [[PubMed](#)]

4. McConkey, B.J.; Sobolev, V.; Edelman, M. The performance of current methods in ligand-protein docking. *Curr. Sci.* **2002**. [\[CrossRef\]](#)
5. Hassan, A.H.E.; Yoo, S.Y.; Lee, K.W.; Yoon, Y.M.; Ryu, H.W.; Jeong, Y.; Shin, J.S.; Kang, S.Y.; Kim, S.Y.; Lee, H.H.; et al. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38- α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. *Eur. J. Med. Chem.* **2019**, *180*, 253–267. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Li, Y.; Cao, Y.; Xu, J.; Qiu, L.; Xu, W.; Li, J.; Song, Y.; Lu, B.; Hu, Z.; Zhang, J. Esculentoside A suppresses lipopolysaccharide-induced pro-inflammatory molecule production partially by casein kinase 2. *J. Ethnopharmacol.* **2017**, *198*, 15–23. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Gao, W.; Kim, J.Y.; Anderson, J.R.; Akopian, T.; Hong, S.; Jin, Y.Y.; Kandror, O.; Kim, J.W.; Lee, I.A.; Lee, S.Y.; et al. The cyclic peptide ecumicin targeting CLpC1 is active against *Mycobacterium tuberculosis* in vivo. *Antimicrob. Agents Chemother.* **2015**, *59*, 880–889. [\[CrossRef\]](#)
8. Schmitz, K.R.; Carney, D.W.; Sello, J.K.; Sauer, R.T. Crystal structure of *Mycobacterium tuberculosis* ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding and substrate delivery. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E4587–E4595. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Chawla, Y.; Upadhyay, S.; Khan, S.; Nagarajan, S.N.; Forti, F.; Nandicoori, V.K. Protein kinase B (PknB) of *Mycobacterium tuberculosis* is essential for growth of the pathogen in vitro as well as for survival within the host. *J. Biol. Chem.* **2014**. [\[CrossRef\]](#)
10. Aggarwal, A.; Parai, M.K.; Shetty, N.; Wallis, D.; Woolhiser, L.; Hastings, C.; Dutta, N.K.; Galaviz, S.; Dhakal, R.C.; Shrestha, R.; et al. Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13. *Cell* **2017**, *170*, 249–259.e25. [\[CrossRef\]](#)
11. Crellin, P.K.; Brammananth, R.; Coppel, R.L. Decaprenylphosphoryl- β -D-Ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in *Mycobacterium smegmatis*. *PLoS ONE* **2011**. [\[CrossRef\]](#)
12. Brecik, M.; Centárová, I.; Mukherjee, R.; Kolly, G.S.; Huszár, S.; Bobovská, A.; Kilacsková, E.; Mokošová, V.; Svetlíková, Z.; Šarkan, M.; et al. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. *ACS Chem. Biol.* **2015**, *10*, 1631–1636. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Stanley, S.; Grant, S.; Kawate, T.; Iwase, N.; Shimizu, M.; Wivagg, C.; Silvis, M.; Kazyanskaya, E.; Aquadro, J.; Golas, A.; et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. *Am. Chem. Soc. Chem. Biol.* **2013**, *7*, 1377–1384.
14. Dessen, A.; Quemard, A.; Blanchard, J.; Jacobs, W.; Sacchettini, J. Crystal structure and function of the isoniazid target of *Mycobacterium tuberculosis*. *Science* **1995**, *267*, 1638–1641. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Kapilashrami, K.; Bommineni, G.R.; MacHutta, C.A.; Kim, P.; Lai, C.T.; Simmerling, C.; Picart, F.; Tonge, P.J. Thiolactomycin-based β -ketoacyl-AcpM synthase a (KasA) inhibitors: Fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. *J. Biol. Chem.* **2013**, *288*, 6045–6052. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Luckner, S.R.; Machutta, C.A.; Tonge, P.J.; Kisker, C. Crystal structures of *Mycobacterium tuberculosis* KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. *Structure* **2009**, *17*, 1004–1013. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Das, S.; Kumar, P.; Bhor, V.; Surolia, A.; Vijayan, M. Invariance and variability in bacterial PanK: A study based on the crystal structure of *Mycobacterium tuberculosis* PanK. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2006**. [\[CrossRef\]](#)
18. Wehenkel, A.; Fernandez, P.; Bellinzoni, M.; Catherinot, V.; Barilone, N.; Labesse, G.; Jackson, M.; Alzari, P.M. The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria. *FEBS Lett.* **2006**, *580*, 3018–3022. [\[CrossRef\]](#)
19. Arifullah, M.; Namsa, N.D.; Mandal, M.; Chiruvella, K.K.; Vikrama, P.; Gopal, G.R. Evaluation of anti-bacterial and anti-oxidant potential of andrographolide and echiodinin isolated from callus culture of *Andrographis paniculata* Nees. *Asian Pac. J. Trop. Biomed.* **2013**. [\[CrossRef\]](#)
20. Prabu, A.; Hassan, S.; Prabuseenivasan; Shainaba, A.S.; Hanna, L.E.; Kumar, V. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in *Mycobacterium tuberculosis*. *J. Mol. Graph. Model.* **2015**. [\[CrossRef\]](#)
21. Navarro-García, V.M.; Luna-Herrera, J.; Rojas-Bribiesca, M.G.; Álvarez-Fitz, P.; Ríos, M.Y. Antibacterial activity of aristolochia brevipes against multidrug-resistant *Mycobacterium tuberculosis*. *Molecules* **2011**, *16*, 7357–7364. [\[CrossRef\]](#)
22. León-Díaz, R.; Meckes, M.; Said-Fernández, S.; Molina-Salinas, G.M.; Vargas-Villarreal, J.; Torres, J.; Luna-Herrera, J.; Jiménez-Arellanes, A. Antimycobacterial neolignans isolated from *Aristolochia taliscana*. *Mem. Inst. Oswaldo Cruz* **2010**. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Jiménez-Arellanes, A.; León-Díaz, R.; Meckes, M.; Tapia, A.; Molina-Salinas, G.M.; Luna-Herrera, J.; Yépez-Mulia, L. Antiprotozoal and antimycobacterial activities of pure compounds from *Aristolochia elegans* rhizomes. *Evid. Based Complement. Altern. Med.* **2012**. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Jiménez-Arellanes, A.; Luna-Herrera, J.; Cornejo-Garrido, J.; López-García, S.; Castro-Mussot, M.E.; Meckes-Fischer, M.; Mata-Espinosa, D.; Marquina, B.; Torres, J.; Hernández-Pando, R. Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment. *BMC Complement. Altern. Med.* **2013**. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Jyoti, M.A.; Nam, K.W.; Jang, W.S.; Kim, Y.H.; Kim, S.K.; Lee, B.E.; Song, H.Y. Antimycobacterial activity of methanolic plant extract of *Artemisia capillaris* containing ursolic acid and hydroquinone against *Mycobacterium tuberculosis*. *J. Infect. Chemother.* **2016**. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Molina-Salinas, G.M.; Bórquez, J.; Ardiles, A.; Said-Fernández, S.; Loyola, L.A.; Yam-Puc, A.; Becerril-Montes, P.; Escalante-Erosa, F.; San-Martin, A.; González-Collado, I.; et al. Bioactive metabolites from the Andean flora. Antituberculosis activity of natural and semisynthetic azorellane and mulinane diterpenoids. *Phytochem. Rev.* **2010**. [\[CrossRef\]](#)
27. Chen, J.J.; Chou, E.T.; Peng, C.F.; Chen, I.S.; Yang, S.Z.; Huang, H.Y. Novel epoxyfuranoid lignans and antitubercular constituents from the leaves of *Beilschmiedia tsangii*. *Planta Med.* **2007**. [\[CrossRef\]](#)

28. Aponte, J.C.; Estevez, Y.; Gilman, R.H.; Lewis, W.H.; Rojas, R.; Sauvain, M.; Vaisberg, A.J.; Hammond, G.B. Anti-infective and cytotoxic compounds present in *Blepharodon nitidum*. *Planta Med.* **2008**. [\[CrossRef\]](#)
29. Mehta, A.; Srivastva, G.; Kachhwaha, S.; Sharma, M.; Kothari, S.L. Antimycobacterial activity of *Citrullus colocynthis* (L.) Schrad. against drug sensitive and drug resistant *Mycobacterium tuberculosis* and MOTT clinical isolates. *J. Ethnopharmacol.* **2013**. [\[CrossRef\]](#)
30. Rojas, R.; Caviedes, L.; Aponte, J.C.; Vaisberg, A.J.; Lewis, W.H.; Lamas, G.; Sarasara, C.; Gilman, R.H.; Hammond, G.B. Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from *Clavija procera*. *J. Nat. Prod.* **2006**. [\[CrossRef\]](#)
31. Changtam, C.; Hongmanee, P.; Suksamrarn, A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. *Eur. J. Med. Chem.* **2010**. [\[CrossRef\]](#)
32. Uc-Cachón, A.H.; Borges-Argáez, R.; Said-Fernández, S.; Vargas-Villarreal, J.; González-Salazar, F.; Méndez-González, M.; Cáceres-Farfán, M.; Molina-Salinas, G.M. Naphthoquinones isolated from *Diospyros anisandra* exhibit potent activity against pan-resistant first-line drugs *Mycobacterium tuberculosis* strains. *Pulm. Pharmacol. Ther.* **2014**. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Dey, D.; Ray, R.; Hazra, B. Antitubercular and antibacterial activity of quinonoid natural products against multi-drug resistant clinical isolates. *Phytother. Res.* **2014**. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Lall, N.; Meyer, J.J.M.; Wang, Y.; Bapela, N.B.; Van Rensburg, C.E.J.; Fourie, B.; Franzblau, S.G. Characterization of intracellular activity of antitubercular constituents from the roots of *Euclea natalensis*. *Pharm. Biol.* **2005**. [\[CrossRef\]](#)
35. van der Kooy, F.; Meyer, J.J.M.; Lall, N. Antimycobacterial activity and possible mode of action of newly isolated neodiospyrin and other naphthoquinones from *Euclea natalensis*. *S. Afr. J. Bot.* **2006**. [\[CrossRef\]](#)
36. Al-Yahya, M.A.; Muhammad, I.; Mirza, H.H.; El-Feraly, F.S. Antibacterial constituents from the rhizomes of *Ferula communis*. *Phytother. Res.* **1998**. [\[CrossRef\]](#)
37. Gordien, A.Y.; Gray, A.I.; Franzblau, S.G.; Seidel, V. Antimycobacterial terpenoids from *Juniperus communis* L. (Cupressaceae). *J. Ethnopharmacol.* **2009**. [\[CrossRef\]](#)
38. Mossa, J.S.; El-Feraly, F.S.; Muhammad, I. Antimycobacterial constituents from *Juniperus procera*, *Ferula communis* and *Plumbago zeylanica* and their in vitro synergistic activity with isonicotinic acid hydrazide. *Phytother. Res.* **2004**. [\[CrossRef\]](#)
39. Lakshmanan, D.; Werngren, J.; Jose, L.; Suja, K.P.; Nair, M.S.; Varma, R.L.; Mundayoor, S.; Hoffner, S.; Kumar, R.A. Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis medicinal herb inhibits drug resistant strains of *Mycobacterium tuberculosis* in vitro. *Fitoterapia* **2011**. [\[CrossRef\]](#)
40. Jiménez-Arellanes, A.; Meckes, M.; Torres, J.; Luna-Herrera, J. Antimycobacterial triterpenoids from *Lantana hispida* (Verbenaceae). *J. Ethnopharmacol.* **2007**. [\[CrossRef\]](#)
41. Favela-Hernández, J.M.J.; García, A.; Garza-González, E.; Rivas-Galindo, V.M.; Camacho-Corona, M.R. Antibacterial and antimycobacterial lignans and flavonoids from *Larrea tridentata*. *Phytother. Res.* **2012**. [\[CrossRef\]](#)
42. Rijo, P.; Simões, M.F.; Francisco, A.P.; Rojas, R.; Gilman, R.H.; Vaisberg, A.J.; Rodríguez, B.; Moiteiro, C. Antimycobacterial metabolites from *Plectranthus*: Royleanone derivatives against *Mycobacterium tuberculosis* strains. *Chem. Biodivers.* **2010**. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Kumar, P.; Singh, A.; Sharma, U.; Singh, D.; Dobhal, M.P.; Singh, S. Anti-mycobacterial activity of plumericin and isoplumericin against MDR *Mycobacterium tuberculosis*. *Pulm. Pharmacol. Ther.* **2013**. [\[CrossRef\]](#)
44. Leitão, F.; Leitão, S.G.; De Almeida, M.Z.; Cantos, J.; Coelho, T.; Da Silva, P.E.A. Medicinal plants from open-air markets in the State of Rio de Janeiro, Brazil as a potential source of new antimycobacterial agents. *J. Ethnopharmacol.* **2013**. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Sureram, S.; Senadeera, S.P.D.; Hongmanee, P.; Mahidol, C.; Ruchirawat, S.; Kittakoop, P. Antimycobacterial activity of bisbenzylisoquinoline alkaloids from *Tiliacora triandra* against multidrug-resistant isolates of *Mycobacterium tuberculosis*. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 2902–2905. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Gupta, S.; Dwivedi, G.R.; Darokar, M.P.; Srivastava, S.K. Antimycobacterial activity of fractions and isolated compounds from *Vetiveria zizanioides*. *Med. Chem. Res.* **2012**. [\[CrossRef\]](#)
47. Azam, S.S.; Abbasi, S.W. Molecular docking studies for the identification of novel melatonergic inhibitors for acetylserotonin-O-methyltransferase using different docking routines. *Theor. Biol. Med. Model.* **2013**, *10*, 63. [\[CrossRef\]](#)
48. Subramani, R.; Narayanasamy, M.; Feussner, K.D. Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens. *3 Biotech* **2017**, *7*, 172. [\[CrossRef\]](#)
49. Espinoza-Moraga, M.; Njuguna, N.M.; Mugumbate, G.; Caballero, J.; Chibale, K. In silico Comparison of Antimycobacterial Natural Products with Known Antituberculosis Drugs. *J. Chem. Inf. Model.* **2013**, *53*, 649–660. [\[CrossRef\]](#)
50. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**. [\[CrossRef\]](#)
51. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.* **2010**. [\[CrossRef\]](#)
52. Brenk, R.; Schipani, A.; James, D.; Krasowski, A.; Gilbert, I.H.; Frearson, J.; Wyatt, P.G. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. *ChemMedChem* **2008**. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Seyedi, S.S.; Shukri, M.; Hassandarvish, P.; Oo, A.; Shankar, E.M.; Abubakar, S.; Zandi, K. Computational Approach Towards Exploring Potential Anti-Chikungunya Activity of Selected Flavonoids. *Sci. Rep.* **2016**, *6*, 24027. [\[CrossRef\]](#)
54. Qiu, J.-X.; Zhou, Z.-W.; He, Z.-X.; Zhang, X.; Zhou, S.-F.; Zhu, S. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. *Drug Des. Dev. Ther.* **2015**, *9*, 841–866. [\[CrossRef\]](#)

55. Natarajan, A.; Sugumar, S.; Bitragunta, S.; Balasubramanyan, N. Molecular docking studies of (4Z, 12Z)-cyclopentadeca-4, 12-dienone from *Grewia hirsuta* with some targets related to type 2 diabetes. *BMC Complement. Altern. Med.* **2015**, *15*, 73. [\[CrossRef\]](#) [\[PubMed\]](#)
56. Ali, M.T.; Blicharska, N.; Shilpi, J.A.; Seidel, V. Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach. *Sci. Rep.* **2018**. [\[CrossRef\]](#) [\[PubMed\]](#)
57. Raju, R.M.; Unnikrishnan, M.; Rubin, D.H.F.; Krishnamoorthy, V.; Kandrór, O.; Akopian, T.N.; Goldberg, A.L.; Rubin, E.J. *Mycobacterium tuberculosis* ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. *PLoS Pathog.* **2012**. [\[CrossRef\]](#)
58. Wolucka, B.A. Biosynthesis of D-arabinose in mycobacteria—A novel bacterial pathway with implications for antimycobacterial therapy. *FEBS J.* **2008**, *275*, 2691–2711. [\[CrossRef\]](#)
59. Schaeffer, M.L.; Agnihotri, G.; Volker, C.; Kallender, H.; Brennan, P.J.; Lonsdale, J.T. Purification and Biochemical Characterization of the *Mycobacterium tuberculosis* B-Ketoacyl-acyl Carrier Protein Synthases KasA and KasB. *J. Biol. Chem.* **2001**. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Portevin, D.; de Sousa-D'Auria, C.; Houssin, C.; Grimaldi, C.; Chami, M.; Daffe, M.; Guilhot, C. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. *Proc. Natl. Acad. Sci. USA* **2004**. [\[CrossRef\]](#) [\[PubMed\]](#)
61. Bhutani, I.; Loharch, S.; Gupta, P.; Madathil, R.; Parkesh, R. Structure, dynamics, and interaction of *Mycobacterium tuberculosis* (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. *PLoS ONE* **2015**, *10*, e0119771. [\[CrossRef\]](#)
62. De Pascoli, I.C.; Nascimento, I.R.; Lopes, L.M.X. Configurational analysis of cubebins and bicubebin from *Aristolochia lagesiana* and *Aristolochia pubescens*. *Phytochemistry* **2006**. [\[CrossRef\]](#)
63. Nascimento, I.R.; Murata, A.T.; Bortoli, S.A.; Lopes, L.M.X. Insecticidal activity of chemical constituents from *Aristolochia pubescens* against *Anticarsia gemmatilis* larvae. *Pest Manag. Sci.* **2004**. [\[CrossRef\]](#)
64. Harmatha, J.; Dinan, L. Biological activities of lignans and stilbenoids associated with plant-insect chemical interactions. *Phytochem. Rev.* **2003**, *2*, 321–330. [\[CrossRef\]](#)
65. Esperandim, V.R.; da Silva Ferreira, D.; Rezende, K.C.S.; Cunha, W.R.; Saraiva, J.; Bastos, J.K.; e Silva, M.L.A.; de Albuquerque, S. Evaluation of the in vivo therapeutic properties of (–)-cubebin and (–)-hinokinin against *Trypanosoma cruzi*. *Exp. Parasitol.* **2013**, *133*, 442–446. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Mascarello, A.; Mori, M.; Chiaradia-Delatorre, L.D.; Menegatti, A.C.O.; Monache, F.D.; Ferrari, F.; Yunes, R.A.; Nunes, R.J.; Terenzi, H.; Botta, B.; et al. Discovery of *Mycobacterium tuberculosis* Protein Tyrosine Phosphatase B (PtpB) Inhibitors from Natural Products. *PLoS ONE* **2013**, *8*, e77081. [\[CrossRef\]](#) [\[PubMed\]](#)
67. Richter, A.; Rudolph, I.; Möllmann, U.; Voigt, K.; Chung, C.; Singh, O.M.P.; Rees, M.; Mendoza-Losana, A.; Bates, R.; Balcells, L.; et al. Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with *Mycobacterium tuberculosis* DprE1. *Sci. Rep.* **2018**, *8*, 13473. [\[CrossRef\]](#) [\[PubMed\]](#)
68. Bjorkelid, C.; Bergfors, T.; Raichurkar, A.K.V.; Mukherjee, K.; Malolanarasimhan, K.; Bandodkar, B.; Jones, T.A. Structural and biochemical characterization of compounds inhibiting *Mycobacterium tuberculosis* pantothenate kinase. *J. Biol. Chem.* **2013**, *288*, 18260–18270. [\[CrossRef\]](#)
69. Yap, C.W. PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. *J. Comput. Chem.* **2011**, *32*, 1466–1474. [\[CrossRef\]](#)
70. Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J. MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. *Nucleic Acids Res.* **2018**, *46*, W486–W494. [\[CrossRef\]](#)
71. Umamaheswari, M.; Aji, C.S.; Asokkumar, K.; Sivashanmugam, T.; Subhadradevi, V.; Jagannath, P.; Madeswaran, A. In silico docking studies of aldose reductase inhibitory activity of selected flavonoids. *Int. J. Drug Dev. Res.* **2012**. [\[CrossRef\]](#)
72. O'Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An Open chemical toolbox. *J. Cheminform.* **2011**. [\[CrossRef\]](#) [\[PubMed\]](#)